In a rodent model of type 2 diabetes (T2D), icovamenib in combination with low-dose semaglutide promoted enhanced glycemic control and b ...

BERKELEY HEIGHTS, NJ, USA and SHANGHAI, China I June 23, 2025 I Corxel Pharmaceuticals Limited (CORXEL), a clinical-stage ...

Hims & Hers delivered record Q1 results and expanded into Europe with the Zava acquisition. Click here to see why HIMS stock ...

Patients who took a GLP-1 drug fared better than those in a control group at keeping their blood glucose levels in a healthy ...

GLP-1 therapies primarily use single-use injectable pens, contributing to medical waste challenges. The pharmaceutical ...

A new potential drug treatment for people with type 2 diabetes and obesity lowers blood sugar and increases fat burning.

A GLP-1 in pill form from Eli Lilly shows promising results for weight loss and Type 2 diabetes treatment in a trial. FDA ...

CHICAGO -- An investigational injectable that only requires dosing once every 4 weeks led to substantial weight loss in ...

Once-monthly maridebart cafraglutide resulted to significant weight loss at 1 year among adults with obesity, regardless of ...

Vaxess Technologies today shared new preclinical data highlighting the capability of its drug delivery patch to deliver ...

For adults with obesity or overweight without diabetes, the novel cyclic adenosine monophosphate-biased glucagon-like peptide ...